An injectable liposome-anchored teriparatide incorporated gallic acid-grafted gelatin hydrogel for osteoarthritis treatment

Intra-articular injection of therapeutics is an effective strategy for treating osteoarthritis (OA), but it is hindered by rapid drug diffusion, thereby necessitating high-frequency injections. Hence, the development of a biofunctional hydrogel for improved delivery is required. In this study, we in...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 14; no. 1; pp. 3159 - 18
Main Authors Li, Guoqing, Liu, Su, Chen, Yixiao, Zhao, Jin, Xu, Huihui, Weng, Jian, Yu, Fei, Xiong, Ao, Udduttula, Anjaneyulu, Wang, Deli, Liu, Peng, Chen, Yingqi, Zeng, Hui
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 31.05.2023
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Intra-articular injection of therapeutics is an effective strategy for treating osteoarthritis (OA), but it is hindered by rapid drug diffusion, thereby necessitating high-frequency injections. Hence, the development of a biofunctional hydrogel for improved delivery is required. In this study, we introduce a liposome-anchored teriparatide (PTH (1–34)) incorporated into a gallic acid-grafted gelatin injectable hydrogel (GLP hydrogel). We show that the GLP hydrogel can form in situ and without affecting knee motion after intra-articular injection in mice. We demonstrate controlled, sustained release of PTH (1–34) from the GLP hydrogel. We find that the GLP hydrogel promotes ATDC5 cell proliferation and protects the IL-1β-induced ATDC5 cells from further OA progression by regulating the PI3K/AKT signaling pathway. Further, we show that intra-articular injection of hydrogels into an OA-induced mouse model promotes glycosaminoglycans synthesis and protects the cartilage from degradation, supporting the potential of this biomaterial for OA treatment. Osteoarthritis is a common disease that causes pain and difficulty moving joints. Here the authors present an injectable gelatin-based hydrogel that slowly releases teriparatide drug to avoid frequent injections, offering a potential solution for patients with osteoarthritis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-023-38597-0